Literature DB >> 16368158

Interaction of targeted liposomes with primary cultured hepatic stellate cells: Involvement of multiple receptor systems.

Joanna E Adrian1, Klaas Poelstra, Gerrit L Scherphof, Grietje Molema, Dirk K F Meijer, Catharina Reker-Smit, Henriëtte W M Morselt, Jan A A M Kamps.   

Abstract

BACKGROUND/AIMS: In designing a versatile liposomal drug carrier to hepatic stellate cells (HSC), the interaction of mannose 6-phosphate human serum albumin (M6P-HSA) liposomes with cultured cells was studied.
METHODS: M6P-HSA was covalently coupled to the liposomal surface and the uptake and binding of 3H-labelled M6P-HSA liposomes by primary rat HSC and liver endothelial cells was determined. The targeting ability of M6P-HSA liposomes to HSC was tested in bile duct ligated rats using immunohistochemical methods.
RESULTS: The association of M6P-HSA liposomes with HSC was 4-fold higher than of control liposomes. An excess of M6P-HSA inhibited this association by 58%, indicating M6P receptor specificity. The scavenger receptor competitor polyinosinic acid abolished association of M6P-HSA liposomes with HSC. M6P-HSA liposomes also amply associated with endothelial cells, which abundantly express scavenger receptors. Endocytosis of M6P-HSA liposomes by HSC was temperature dependent and could be inhibited by monensin. In the fibrotic liver M6P-HSA liposomes co-localised with HSC.
CONCLUSIONS: Coupling of M6P-HSA to liposomes strongly increases the in vitro uptake of these liposomes by HSC and endothelial cells. Both the mannose 6-phosphate receptor and the scavenger receptors are involved in the uptake process. M6P-HSA liposomes are potential drug carriers to HSC in the fibrotic liver.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16368158     DOI: 10.1016/j.jhep.2005.08.027

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  11 in total

1.  MR Imaging of activated hepatic stellate cells in liver injured by CCl4 of rats with integrin-targeted ultrasmall superparamagnetic iron oxide.

Authors:  Qing-Bing Wang; Yu Han; Ting-Ting Jiang; Wei-Min Chai; Ke-Min Chen; Bing-Ya Liu; Li-Fu Wang; Chunfu Zhang; Deng-Bin Wang
Journal:  Eur Radiol       Date:  2010-10-25       Impact factor: 5.315

2.  Cellular distribution of injected PLGA-nanoparticles in the liver.

Authors:  Jin-Kyu Park; Teruo Utsumi; Young-Eun Seo; Yang Deng; Ayano Satoh; William Mark Saltzman; Yasuko Iwakiri
Journal:  Nanomedicine       Date:  2016-03-04       Impact factor: 5.307

Review 3.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

Review 4.  Nanotechnology applications for the therapy of liver fibrosis.

Authors:  Lydia Giannitrapani; Maurizio Soresi; Maria Luisa Bondì; Giuseppe Montalto; Melchiorre Cervello
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 5.  Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver.

Authors:  Scott L Friedman
Journal:  Physiol Rev       Date:  2008-01       Impact factor: 37.312

6.  Targeting 15d-prostaglandin J2 to hepatic stellate cells: two options evaluated.

Authors:  Werner I Hagens; Adriana Mattos; Rick Greupink; Alie de Jager-Krikken; Catharina Reker-Smit; Annemiek van Loenen-Weemaes; I Annette S H Gouw; Klaas Poelstra; Leonie Beljaars
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

7.  Size-dependent cytotoxicity of Fe3O4 nanoparticles induced by biphasic regulation of oxidative stress in different human hepatoma cells.

Authors:  Yuexia Xie; Dejun Liu; Chenlei Cai; Xiaojing Chen; Yan Zhou; Liangliang Wu; Yongwei Sun; Huili Dai; Xianming Kong; Peifeng Liu
Journal:  Int J Nanomedicine       Date:  2016-07-29

8.  Targeting brain cells with glutathione-modulated nanoliposomes: in vitro and in vivo study.

Authors:  Heba F Salem; Sayed M Ahmed; Ashraf E Hassaballah; Mahmoud M Omar
Journal:  Drug Des Devel Ther       Date:  2015-07-20       Impact factor: 4.162

Review 9.  Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers.

Authors:  Leonard Kaps; Detlef Schuppan
Journal:  Cells       Date:  2020-09-03       Impact factor: 6.600

Review 10.  Homing in on the hepatic scar: recent advances in cell-specific targeting of liver fibrosis.

Authors:  Ross Dobie; Neil C Henderson
Journal:  F1000Res       Date:  2016-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.